



Onco-Hematology pipeline



IGF-1R, Insulin-like Growth Factor 1 Receptor; VISTA, V-domain Ig suppressor of T-cell Activation

This chart includes investigational compounds and/or investigational uses of approved products, for which efficacy and safety have not been established. Approved products should be used in accordance with their prescribing information. Information about the trials can be found at www.ClinicalTrials.gov


Onco-Hematology pipeline



† Encorafenib + cetuximab approved for *BRAFV600E* mutant mCRC, after prior therapy; encorafenib + binimetinib approved for *BRAF*-mutant melanoma
 1, In licensing with Array (Pfizer inc. Group), Boulder USA ; 2, In licensing with PUMA Biotechnology inc., Los Angeles USA; 3, In licensing with ATARA Biotherapeutics inc. South San Francisco USA.
 The sponsor of these studies could be Pierre Fabre Medicament, Pfizer, Array BioPharma, Puma Biotechnology, Inc or Atara Biotherapeutics.

This chart includes investigational compounds and/or investigational uses of approved products, for which efficacy and safety have not been established. Approved products should be used in accordance with their prescribing information. Information about the trials can be found at www.ClinicalTrials.gov

Onco-Hematology pipeline



* In licensing with Otsuka Pharmaceutical inc. Tokyo Japan.

This chart includes investigational compounds and/or investigational uses of approved products, for which efficacy and safety have not been established. Approved products should be used in accordance with their prescribing information. Information about the trials can be found at www.ClinicalTrials.gov